Leica Microsystems and Cell Signaling Technology (CST) have agreed a partnership to validate CST antibodies on the Cell DIVE multiplexed imaging solution.
As an open multiplexing system, Cell DIVE allows researchers to design custom antibody biomarker panels.
James O’Brien, Vice President Life Sciences at Leica Microsystems, said: “Instead of spending time validating antibodies, the pre-validated antibodies allow researchers to design their individual panels and obtain accurate and reproducible data quickly.”
The iterative staining workflow allows over 60 biomarkers to be visualised on one sample. With Leica-quality images of whole tissue sections at the single-cell level, Cell DIVE can deepen scientists’ understanding of the tissue microenvironment in key fields such as cancer research.
Under the partnership, Leica Microsystems has tested CST antibodies conjugated to standard fluorophores and verified their compatibility with the Cell DIVE multiplexing workflow.
“Antibody specificity, reproducibility, and instrument compatibility are critical for researchers using spatial biology approaches. Our partnership with Leica Microsystems, and their Cell DIVE instrument, shows how we can work together to ensure efficient, accurate data collection, and empower scientific discoveries,” said Roby Polakiewicz, Chief Scientific Officer at Cell Signaling Technology.
Image: Normal colon iteratively stained with over 30 CST antibodies using the Cell DIVE multiplexed imaging solution. Biomarkers displayed CD8A (orange); CD11B (mauve); CD68 (magenta); CD79A(red); GZMB (green); PanCK (emerald); CD45 (aqua).
